AGN Allergan plc

148.23
-2.63  -2%
Previous Close 150.86
Open 149.02
Price To Book 0.71
Market Cap 49995896665
Shares 337,285,952
Volume 3,573,740
Short Ratio 1.34
Av. Daily Volume 2,227,661

SEC filingsSee all SEC filings

  1. 8-K - Current report 181187576
  2. 8-K - Current report 181178914
  3. 424B2 - Prospectus [Rule 424(b)(2)] 181174187
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181168005
  5. 8-K - Current report 181151432

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval (third indication) announced October 3, 2017.
Botox
Forehead lines
BLA filing announced July 31, 2017.
ABP 980
Herceptin biosimilar
Phase 2 data due 2019.
RTGel in combination with BOTOX
Overactive Bladder (OAB)
Approval announced March 20, 2017.
JUVÉDERM VOLLURE
Correction of moderate to severe facial wrinkles and folds
Phase 3 to be initiated 2H 2018 with data due 2020.
Brazikumab
Crohn's disease
Phase 3 enrollment to be completed 2H 2018.
Bimatoprost
Androgenic Alopecia
Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Botox
Depression
Phase 3 data released December 18, 2017 - primary endpoint met.
Cariprazine
Bipolar I depression
Phase 2b trial ongoing.
RORγt agonist
Psoriasis
Approval announced November 13, 2017.
Cariprazine
Maintenance Treatment of Schizophrenia
Phase 3 trial to be initiated 1H 2019.
ATOGEPANT
Prophylaxis (migraine)
Phase 3 initiated October 2016. Data due 1H 2019.
RAPASTINEL
Major depressive disorder (MDD)
Phase 3 initiated 2H 2017 with top-line data due 2020.
RELAMORELIN
Diabetic Gastroparesis
CRL issued August 21, 2018.
ESMYA (ulipristal acetate)
Uterine Fibroids
Phase 3 trial to be initiated 2019.
ABICIPAR
Diabetic macular edema (DME)
Phase 3 trial has been initiated.
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)
Phase 3 data released July 19, 2018. Primary endpoint met. BLA filing due 1H 2019.
ABICIPAR
Age-related macular degeneration (AMD)
sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI)
Approved January 19, 2017.
Oxymetazoline HCl cream 1.0%
Facial Erythema (Redness) Associated with Rosacea
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
FDA Approval announced October 2, 2018.
Sarecycline
Severe acne vulgaris
Phase 3 data released April 3, 2018. Primary endpoint met. sNDA filing due 2H 2018.
Cariprazine
Bipolar I Depression
NDA filing due 1Q 2019.
UBROGEPANT
Migraine
Phase 2 trial to be initiated 2H 2018.
Brazikumab
Ulcerative colitis
Phase 3 trial to be initiated 2H 2018.
Brimo DDS
Geographic atrophy
Phase 3 safety data due 1H 2019.
Bimatoprost
Open-angle glaucoma or ocular hypertension

Latest News

  1. Should Warren Buffett — And You — Buy More TEVA Stock Right Now?
  2. Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals
  3. Is Allergan plc (AGN) A Good Stock To Buy?
  4. Okta (OKTA) Q3 Earnings and Revenues Surpass Estimates
  5. Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger
  6. Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval
  7. David Tepper's Top 5 Holdings
  8. Stocks That Fell to 3-Year Lows in the Week of Nov. 30
  9. EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE?
  10. Recent Analysis Shows Applied Optoelectronics, J.M. Smucker, RYB Education, Inc. Sponsored ADR, Workiva, Bilibili Inc. Sponsored ADR, and Allergan plc Market Influences — Renewed Outlook, Key Drivers of Growth
  11. A Pharmaceutical Company With a Resilient Portfolio and Solid Pipeline
  12. A Look at Celgene’s Revlimid Label Expansion Initiatives in 2018
  13. 5 Biotech Stocks to Scoop Up for Big Dividends
  14. Spinal-cord stimulators help some patients, injure others
  15. Breast implants reveal problems in tracking device safety
  16. 3 Stocks That Are Absurdly Cheap Right Now
  17. Allergan Makes New Appointments to Finance Leadership Team
  18. Ride the Wellness Wave at Sea with Shares of this Unique Spa Operator
  19. ICR Hires BlackRock Executive to Lead Governance Advisory Solutions Group

SEC Filings

  1. 8-K - Current report 181187576
  2. 8-K - Current report 181178914
  3. 424B2 - Prospectus [Rule 424(b)(2)] 181174187
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181168005
  5. 8-K - Current report 181151432
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181148683
  7. 8-K - Current report 181145467
  8. 8-K - Current report 181044922
  9. 8-K - Current report 181001545
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18990039